Shengjia Shi
- Cancer Research top 5%
- Cancer-related molecular mechanisms research 4
-
- Immunotherapy and Immune Responses 3
- Oncology top 10%
-
- RNA Research and Splicing 4
- Renal and related cancers 2
- Reproductive Medicine top 10%
- Sperm and Testicular Function 2
-
- Prostate Cancer Treatment and Research 6
-
- Quantum Dots Synthesis And Properties 2
-
- Radiopharmaceutical Chemistry and Applications 2
- Cited by
- Cancer ResearchImmunologyOncology
- Partner nations
- ChinaUnited States
In The Last Decade
Shengjia Shi
24 papers receiving 938 citations
Peers
Comparison fields: 5 of 75
- Cancer Research 391
- Immunology 211
- Oncology 256
- Molecular Biology 448
- Reproductive Medicine 45
Countries citing papers authored by Shengjia Shi
This map shows the geographic impact of Shengjia Shi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shengjia Shi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shengjia Shi more than expected).
Fields of papers citing papers by Shengjia Shi
This network shows the impact of papers produced by Shengjia Shi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shengjia Shi. The network helps show where Shengjia Shi may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Shengjia Shi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2024 | 3 | |
| 3 | 2023 | 1 | |
| 4 | 2023 | 12 | |
| 5 | 2023 | 11 | |
| 6 | 2023 | 11 | |
| 7 | 2022 | 18 | |
| 8 | 2021 | 9 | |
| 9 | 2021 | 20 | |
| 10 | 2020 | 26 | |
| 11 | 2020 | 3 | |
| 12 | 2019 | 10 | |
| 13 | 2019 | 57 | |
| 14 | 2019 | 44 | |
| 15 | 2018 | 17 | |
| 16 | 2018 | 55 | |
| 17 | [miR-590-5p inhibits A375 cell invasion and migration in malignant melanoma by directly inhibiting YAP1 expression]. | 2017 | 4 |
| 18 | 2015 | 271 | |
| 19 | 2014 | 80 | |
| 20 | 2013 | 149 |
About Shengjia Shi
Shengjia Shi is a scholar working on Cancer Research, Reproductive Medicine and Immunology and Allergy, having authored 25 papers that have together received 944 indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (6 papers), Cancer-related molecular mechanisms research (4 papers), RNA Research and Splicing (4 papers), Immunotherapy and Immune Responses (3 papers), Quantum Dots Synthesis And Properties (2 papers), Radiopharmaceutical Chemistry and Applications (2 papers), Renal and related cancers (2 papers) and Sperm and Testicular Function (2 papers). The work is most often cited by research in Cancer Research (391 citations), Immunology (211 citations) and Oncology (256 citations). Shengjia Shi has collaborated with scholars based in China and United States. Frequent co-authors include Lijuan Wang, Weihong Wen, Yunhui Li, Yong Jin, Bo Yu, Angang Yang, Zhangyan Guo, Ming Wei, Donghui Han and Yan–Ling Meng. Their work appears in journals such as PLoS ONE, Cancer Research and Scientific Reports.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.